Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02134431 · ClinicalTrials.gov registry record
Relationship of Tenofovir With HIV-1 Suppression in ex Vivo Tissue in Adolescents
A clinical trial of Human Immunodeficiency Virus, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- 13
- Enrollment target
- 1
- Study location
NCT02134431 is a study of Human Immunodeficiency Virus that has completed, run by University of California, Los Angeles. The registered enrollment target is 13 participants, below the 184-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02134431, a study of Human Immunodeficiency Virus, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
Microbicides are topical medicines that can prevent infection by Human Immunodeficiency Virus (HIV). Microbicide medicine has yet to be studied in adolescents, a key group that is becoming infected with HIV all over the world. From past research, we know that at different ages people experience age-related changes in their bodies that can cause differences in how they process medications. In this study, gut tissue samples (or gut biopsies) from 12 HIV-negative volunteers will be collected. These pieces of tissue will be infected with HIV in the laboratory to develop a model that can be used to test certain drugs against the HIV infection. We can use this tissue to test a drug called tenofovir against HIV infection. We will determine whether this drug can decrease HIV infection in the gut biopsies. In this study, we will also measure HIV levels and the levels of tenofovir in gut and blood samples in 12 people who are already taking this drug. This information can determine whether levels of drug found in the gut can protect it from HIV. The results can be compared to other age groups of adolescents and adults. Subjects will undergo a common procedure called a lower endoscopy (this can be a colonoscopy or a flexible sigmoidoscopy) to obtain gut biopsy samples. The central hypothesis is that tissue drug profiles of tenofovir (TFV) and its active component, tenofovir disoproxil fumarate (TDF), and tissue infectibility vary between younger (10-14 years old) versus older adolescents (18-21 years old), and that both differ from adults (\>21 years). Specifically, younger HIV positive adolescents will have lower levels of tissue tenofovir compared to older HIV positive adolescents and adults in an age-dependent manner. Additionally, biopsies from younger HIV negative adolescents will have: 1) higher rates of infection compared to biopsies from older HIV negative adolescents infected with a lower dose of virus; and 2) lower percent suppression of tissue infectivity compared
Conditions Studied
Interventions
- DEVICE flexible sigmoidoscopy or colonoscopy with biopsies
Study Locations (1)
California
- UCLA Clinical and Translational Research Center (CTRC) - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02134431
The ClinicalTrials.gov registry entry for NCT02134431 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 184-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (93% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Human Immunodeficiency Virus appearing as the primary indexed condition, and to 1 intervention - of which flexible sigmoidoscopy or colonoscopy with biopsies is the first listed.
NCT02134431 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02134431 about?
NCT02134431 is a clinical study titled "Relationship of Tenofovir With HIV-1 Suppression in ex Vivo Tissue in Adolescents". Microbicides are topical medicines that can prevent infection by Human Immunodeficiency Virus (HIV). Microbicide medicine has yet to be studied in adolescents, a key group that is becoming infected with HIV all over the world. From past research, we know that at different ages people experience age-...
What is the current status of trial NCT02134431?
This trial is currently completed. The enrollment target is 13 participants. The study started on 2014-05. Estimated completion is 2015-06.
What conditions does trial NCT02134431 study?
This clinical trial studies the following conditions: Human Immunodeficiency Virus.
What interventions are being tested in trial NCT02134431?
The interventions under investigation include: flexible sigmoidoscopy or colonoscopy with biopsies (DEVICE).
Who is sponsoring clinical trial NCT02134431?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02134431 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Immunodeficiency Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
Baricitinib for Reduction of HIV - CNS
RECRUITING · Phase 2
-
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
RECRUITING · Phase 2
-
Harm Reduction in HIV Primary Care for PLWH Who Use Drugs
RECRUITING
-
Tulane Abdominal Transplant Institute (TATI) of Solid Organ Transplantation of HIV-Positive Recipients From HIV-Positive Donors
RECRUITING
-
V+PSF-M for Tobacco Cessation in HIV Care in India
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.